Clinical trial

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

NCT00229697

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-10-01

PhasePHASE2

Study timeline

Study start (unknown)2003-10-01Date precision: month

Registry last updated2015-10-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Interventions

GefitinibDRUG · verified · RxNorm: gefitinib

TamoxifenDRUG · verified · RxNorm: tamoxifen

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

New YorkNew York, United States1 St LouisMissouri, United States1 TorontoOntario, Canada1 MadridSpain1 BarcelonaSpain1 MontrealQuebec, Canada1 BrusselsBelgium1 LyonFrance1 OttawaOntario, Canada1 EdmontonAlberta, Canada1 ManchesterUnited Kingdom1 CalgaryAlberta, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00229697 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.